Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Chronic Immune Thrombocytopenia (ITP) – Clinical and Mechanistic Proof-of-Efficacy Study
2011-000241-21Phase 2Terminated
- Sponsor
- GSK
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of belimumab in immune thrombocytopenic purpura (ITP) and immune thrombocytopenia (ITP), sponsored by GSK. Primary endpoint: Change from baseline in platelet count. Started May 2011; status: terminated.
02
Drugs
belimumab
03
Conditions
immune thrombocytopenic purpura (ITP)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2011-000241-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000241-21.